Small-Cap Firms Dominate Thursday’s Gains. In this article, we are going to take a look at where Plus Therapeutics Inc.

A 68-year-old man with prostate cancer develops penile metastases, a rare but serious complication, reinforcing the need for ...

Nanobiotix S.A. Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose ...

Information on the survival of urothelial cancer (UCa) patients with brain metastases (BM) is largely unreliable due to the rarity of such cases. Previous studies that have attempted to capture the ...

A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic ...

Investigators found that some patients with high-risk nonmetastatic hormone-sensitive prostate cancer were understaged by ...

REYOBIQ™ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and ...

Plus Therapeutics shares are trading higher by 183% during Thursday's session. The company announced that the FDA accepted ...

Active surveillance (AS) following a complete clinical response to neoadjuvant chemoradiotherapy was noninferior to standard ...

The test can be used to better stratify cancer patients and determine the likelihood of breast cancer metastasizing.

Purpose: To investigate the gut microbiome of lung cancer patients with brain metastases undergoing radiotherapy, identify key microorganisms associated with radiotherapy response, and evaluate their ...

Current guidelines lack consensus and rely on lower-quality evidence, according to the author of new research.